Detalhe da pesquisa
1.
Implementing Outcomes-Based Managed Entry Agreements for Rare Disease Treatments: Nusinersen and Tisagenlecleucel.
Pharmacoeconomics
; 39(9): 1021-1044, 2021 09.
Artigo
Inglês
| MEDLINE | ID: mdl-34231135
2.
Pooling of urine specimens allows accurate and cost-effective genetic detection of Chlamydia trachomatis in Lithuania and other low-resource countries.
Scand J Infect Dis
; 39(3): 209-12, 2007.
Artigo
Inglês
| MEDLINE | ID: mdl-17366049